CATALYSIS SL
Clinical Trials
52
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (52 trials with phase data)• Click on a phase to view related trials
Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
- Conditions
- Depression ModerateDepression MildDepressionPost-COVID-19 Syndrome
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 100
- Registration Number
- NCT06496087
- Locations
- 🇨🇴
Fundación CR INVESTIGATION INSTITUTE, Bogotá, Bogotá DC, Colombia
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
- Conditions
- InflammationPost-COVID-19 SyndromeFatigueDyspneaCoughCOVID-19
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 200
- Registration Number
- NCT06437210
- Locations
- 🇨🇴
Fundación CR INVESTIGATION INSTITUTE, Bogotá, Bogotá DC, Colombia
Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children
- Conditions
- Atopic Dermatitis and Related ConditionsAtopic Dermatitis EczemaAtopic DermatitisAtopic Dermatitis \(AD\)
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 58
- Registration Number
- NCT06361992
- Locations
- 🇷🇸
University of Niš Faculty of Medicine, Department of Dermatology and Venereology, University Clinical Center of Niš, Niš, Nišava, Serbia
🇷🇸City Institute for Skin and Venereal Diseases Belgrade, Belgrade, Serbia
🇷🇸University of Belgrade Faculty of Medicine, University Clinical Center of Serbia, Belgrade, Serbia
Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours
- Conditions
- Advanced Solid TumorCentral Nervous System TumorGerm Cell TumorSarcomaLymphoma, HodgkinPediatric CancerAdvanced Cancer
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 40
- Registration Number
- NCT06363201
- Locations
- 🇭🇳
Hospital Escuela, Tegucigalpa (Honduras), Tegucigalpa, Francisco Morazan, Honduras
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
- Conditions
- Papilloma Viral InfectionCIN1LSIL, Low Grade Squamous Intraepithelial Lesion
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Catalysis SL
- Target Recruit Count
- 120
- Registration Number
- NCT05916911
- Locations
- 🇪🇸
Hospital Ruber Internacional, Madrid, Spain
🇪🇸Hospital Clinico San Carlos, Madrid, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next